Scarica l'app Stockscreener
208.45
0.04%
0.09
Pre-mercato:
206.51
-1.94
-0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$208.36
Aprire:
$208.14
Volume 24 ore:
488.00K
Relative Volume:
0.49
Capitalizzazione di mercato:
$22.98B
Reddito:
$10.52B
Utile/perdita netta:
$999.00M
Rapporto P/E:
24.93
EPS:
8.3628
Flusso di cassa netto:
$1.22B
1 W Prestazione:
+0.31%
1M Prestazione:
+10.16%
6M Prestazione:
+15.73%
1 anno Prestazione:
+19.11%
Intervallo 1D:
$207.11
$209.76
Intervallo di 1 settimana:
$203.89
$213.50
Portata 52W:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
208.45 | 22.97B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider - GlobeNewswire Inc.
Elo Mutual Pension Insurance Co Makes New $2.03 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) EVP sells shares and disposes stock for taxes - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan - Stock Titan
Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale - Stock Titan
Quest Diagnostics (DGX) SVP sells and withholds shares under plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP covers tax obligations with share sale - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports tax-withholding stock disposition on Form 4 - Stock Titan
Quest Diagnostics Remains a Dominant Competitor in Independent Labs - Morningstar
Catherine Doherty reports 27,598 DGX share dispositions in Form 144 (NYSE: DGX) - Stock Titan
DGX insider sale notice (DGX) — 526 vested shares; prior 1,111 sold - Stock Titan
Insider sale notice for DGX (DGX): Plewman lists proposed share disposals - Stock Titan
Victory Capital Management Inc. Sells 465,252 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
DGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quest Diagnostics launches AI tool to analyze lab results By Investing.com - Investing.com Canada
DGX (NYSE: DGX) Form 144 shows proposed sale of 10,000 shares - Stock Titan
Quest Diagnostics Rolls Out Gemini-Powered AI Tool to Explain Lab Results - marketscreener.com
Quest Diagnostics introduces AI companion to help patients understand and act on lab test results - marketscreener.com
New Quest AI chat uses 5 years of lab data to spot potential health risks - Stock Titan
Quest Diagnostics Inc. (NYSE:DGX) Stands Out as a Sustainable Dividend Stock - ChartMill
Quest Diagnostics Incorporated $DGX Position Lowered by IVY Lane Capital Management LLC - MarketBeat
Bahl & Gaynor Inc. Decreases Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
APG Asset Management N.V. Cuts Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Bought by American Century Companies Inc. - MarketBeat
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Vestmark Advisory Solutions Inc. - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Quest Diagnostics (NYSE:DGX) Sets New 1-Year HighWhat's Next? - MarketBeat
Quest Diagnostics stock reaches all-time high at 213.21 USD By Investing.com - Investing.com Canada
Quest Diagnostics appoints Beauvalot to SVP, chief strategy and M&A officer - ROI-NJ
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
In Insight Molecular Diagnostics Inc. Enters into A Specimen Collection Agreement with Quest Diagnostics Incorporated - marketscreener.com
Quest Diagnostics Announces Appointment of Benjamin Beauvalot as Senior Vice President, Chief Strategy and M&A Officer - marketscreener.com
After nearly 80 deals, Quest Diagnostics names new M&A chief - Stock Titan
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Insight Molecular Diagnostics Inc. has reached a service agreement with Quest Diagnostics. - Bitget
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference - Finviz
Citigroup Inc. Acquires 25,666 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth - Yahoo Finance
Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock - Defense World
Quest Diagnostics (NYSE:DGX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Compass Wealth Management LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - Defense World
ANTIPODES PARTNERS Ltd Has $11.76 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 1,111 Shares of Stock - MarketBeat
Quest Diagnostics (NYSE: DGX) CEO awarded options and RSUs, shares withheld for taxes - Stock Titan
Quest Diagnostics (DGX) EVP logs stock sale, option and RSU awards - Stock Titan
Quest Diagnostics (DGX) SVP logs option, RSU grants and tax share disposals - Stock Titan
Dividend plan boosts Quest Diagnostics (NYSE: DGX) director holdings - Stock Titan
Quest Diagnostics (DGX) director acquires 67 shares through dividend reinvestment - Stock Titan
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
2.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):